孕期瓦尔酸暴露会诱导新生儿大脑和状的组织特异性转录组变化,在的老鼠模型中,GAERS
Fiona Qiu1, Yifan Huang1, Katarzyna M Dziegielewska1
1Department of Neuroscience, School of Translational Medicine, Monash University, Melbourne, Victoria, Australia.
The European journal of neuroscience
|May 15, 2025
概括
孕期暴露于氨酸显著影响胎儿大脑发育,改变胆脉和皮质中的基因表达. 这种氨酸暴露可能会导致后代的神经发育缺陷.
科学领域:
- 神经科学是一个神经科学.
- 发展生物学 发展生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- 瓦尔酸是治疗的重要抗发作药物.
- 产前暴露于氨酸与儿童神经发育缺陷风险增加有关.
- 这些缺陷背后的特定分子机制仍然不完全理解.
研究的目的:
- 为了研究孕期瓦尔酸暴露对发育中的大脑转录组的影响.
- 为了比较瓦尔酸对大脑皮层和在出生后的早期发育中的胆脉的影响.
- 为了确定潜在的分子标,有助于酸诱导的神经毒性.
主要方法:
- 使用了来自斯特拉斯堡的遗传缺席鼠 (GAERS) 模型.
- 通过饮食给孕大鼠从交配前到妊娠期间通过饮食给药瓦尔酸盐.
- 在大脑皮层和从出生后第5天的幼的侧面状结质组织上进行RNA测序.
- 在暴露于氨酸和对照组之间进行了基因表达差异分析.
主要成果:
- 孕期的瓦尔酸暴露导致了显著的转录基因变异,其中5,694个基因在胆脉中受影响,而在皮质中只有214个基因受影响.
- 冠状交叉体中的失调基因包括离子通道,金属载体 (例如,Slc4a家族) 和药物载体.
- 与中枢神经系统发育,药物代谢和免疫反应相关的基因在两种组织中都发生了变化,在胆脉中影响更为明显.
结论:
- 孕期的瓦尔酸暴露对状交叉体转录组的影响比大脑皮层的影响更深远,更明显.
- 这些发现表明,状可能是理解氨酸诱导的发育神经毒性的关键目标.
- 识别这些转录基因变化可能会导致新的治疗策略,以减轻氨酸的不良影响.
相关概念视频
Antiepileptic Drugs: GABAergic Pathway Potentiators
γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for their...
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for their...
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...


